LENZ Therapeutics Files 8-K
Ticker: LENZ · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, company-information
TL;DR
LENZ Therapeutics filed an 8-K on April 3rd, updating on corporate events.
AI Summary
LENZ Therapeutics, Inc. filed an 8-K on April 3, 2024, to report other events and financial statements. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is incorporated in Delaware and has its principal executive offices in Del Mar, California.
Why It Matters
This filing provides an update on significant corporate events and financial information for LENZ Therapeutics, Inc., which may impact investors' understanding of the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, primarily reporting corporate information and not detailing specific financial performance or material events.
Key Players & Entities
- LENZ Therapeutics, Inc. (company) — Registrant
- Graphite Bio, Inc. (company) — Former company name
- Integral Medicines, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Del Mar, California (location) — Principal executive offices
- April 3, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by LENZ Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of April 3, 2024.
What were the previous names of LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. was formerly known as Graphite Bio, Inc. (name change on March 12, 2021) and Integral Medicines, Inc. (name change on June 22, 2020).
In which state is LENZ Therapeutics, Inc. incorporated?
LENZ Therapeutics, Inc. is incorporated in Delaware.
What is the address of LENZ Therapeutics, Inc.'s principal executive offices?
The principal executive offices of LENZ Therapeutics, Inc. are located at 445 Marine View Ave., Ste. #320, Del Mar, California 92014.
What is the SIC code for LENZ Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for LENZ Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-03 07:32:00
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market
Filing Documents
- lenz-20240403.htm (8-K) — 28KB
- exhibit991-8xk.htm (EX-99.1) — 24KB
- exhibit992-8xk.htm (EX-99.2) — 15KB
- exhibit992-8xk001.jpg (GRAPHIC) — 56KB
- exhibit992-8xk002.jpg (GRAPHIC) — 279KB
- exhibit992-8xk003.jpg (GRAPHIC) — 141KB
- exhibit992-8xk004.jpg (GRAPHIC) — 90KB
- exhibit992-8xk005.jpg (GRAPHIC) — 84KB
- exhibit992-8xk006.jpg (GRAPHIC) — 81KB
- exhibit992-8xk007.jpg (GRAPHIC) — 81KB
- exhibit992-8xk008.jpg (GRAPHIC) — 80KB
- exhibit992-8xk009.jpg (GRAPHIC) — 90KB
- exhibit992-8xk010.jpg (GRAPHIC) — 95KB
- exhibit992-8xk011.jpg (GRAPHIC) — 82KB
- exhibit992-8xk012.jpg (GRAPHIC) — 128KB
- exhibit992-8xk013.jpg (GRAPHIC) — 46KB
- 0001815776-24-000035.txt ( ) — 2044KB
- lenz-20240403.xsd (EX-101.SCH) — 2KB
- lenz-20240403_lab.xml (EX-101.LAB) — 23KB
- lenz-20240403_pre.xml (EX-101.PRE) — 13KB
- lenz-20240403_htm.xml (XML) — 3KB
01 Other Information
Item 8.01 Other Information. Press Release and Corporate Presentation On April 3, 2024, LENZ Therapeutics, Inc. (the "Company") issued a press release ("Press Release") announcing topline results from its Phase 3 CLARITY clinical trials of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. As part of the Press Release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on April 3, 2024 (the "Webcast") to discuss the topline results. The Press Release and the corporate presentation to be used in connection with the Webcast are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. Channels for Disclosure of Information Investors and others should note that the Company may announce material information to the public through filings with the Securities and Exchange Commission, its website (https://ir.lenz-tx.com/), press releases, public conference calls, and public webcasts. The Company uses these channels, as well as social media, to communicate with the public about the Company, its product candidates and other matters. As such, investors, the media and others are encouraged to review the information disclosed through the Company's social media and other channels listed above as such information could be deemed to be material information. Please note that this list may be updated from time to time.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated April 3, 2024. 99.2 CLARITY Presentation, dated April 3, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 3, 2024 LENZ THERAPEUTICS, INC. By: /s/ Evert Schimmelpennink Name: Evert Schimmelpennink Title: Chief Executive Officer